Dose-escalation study of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacement
Titel:
Dose-escalation study of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacement
Auteur:
Eriksson, Bengt I. Borris, Lars C. Dahl, Ola E. Haas, Sylvia Huisman, Menno V. Kakkar, Ajay K. Misselwitz, Frank Muehlhofer, Eva Kälebo, Peter